Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

NCT02180711 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT02180711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02180711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Lead sponsor
Acerta Pharma BV
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 29, 2014
Completion date
December 11, 2028
Enrollment
113 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

non hodgkin lymphoma